|
The deal is Merck’s largest since 2015, when it spent $17bn on acquiring Sigma-Aldrich, also a life sciences specialist.
|
 |
|
Ionis has forecast peak sales of $2bn for Tryngolza as it seeks to harness first-mover advantage.
|
|
|
Amid the debut of positive Phase I data, the biotech will push its lead asset further down the clinical pipeline in endometriosis and pattern hair loss.
|
|
|
The collaboration will see the companies gather and analyse data from many patient samples.
|
|
|
Recordati will handle regulatory filings and commercial operations ex-US, including supporting early access initiatives.
|
|
